TriReme said that it has recently received clearance from the FDA for the GliderXtreme catheter, a highly differentiated advanced balloon catheter system with an expanded matrix of sizes including longer balloon lengths, an atraumatic tapered tip and shaft construction reinforced for torque transmission and exceptional pushability.

GliderXtreme is designed to cross difficult and highly diseased lesions to restore blood flow in complex anatomy.

IDEV’s self-expanding Supera interwoven nitinol stent is a new stent platform designed for the treatment of biliary and peripheral artery diseases. The Supera stent has received CE mark approval in Europe for biliary and peripheral vascular indications and is currently the focus of a prospective, FDA-IDE approved, single-arm clinical trial in 258 patients at up to 40 sites in the US.

IDEV is focused on developing and adding highly differentiated products to its portfolio. IDEV expects to launch the GliderXtreme in the third quarter of 2010.

Eitan Konstantino, president and CEO of TriReme, said: “IDEV is building a strong global foundation, which makes it an ideal partner for us. IDEV’s proven commercial capabilities are undeniable.

“In addition, both companies are engaged in the development of future tools for the PAD market, IDEV with its durable, flexible, and easy-to-use Supera stent and TriReme with the GliderXtreme, a next generation balloon catheter technology designed to cross a broad range of lesions. We look forward to working with IDEV to drive market adoption.”

Christopher Owens, president and CEO of IDEV, said: “IDEV and TriReme are both creating advanced, innovative products to fill significant unmet needs in rapidly expanding medical device markets.

“We are very impressed with TriReme’s catheter products and development capabilities. Given the promising results and growth opportunities we are experiencing with our Supera stent, adding a complementary and technologically advanced product offering makes sense both strategically and clinically. We look forward to working closely with TriReme.”